CIDRAP Database Tracks 156 Coronavirus Vaccine Candidates

The University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) listed 156 coronavirus vaccine candidates on November 11, 2026, spanning 11 viruses, 13 vaccine platforms and 7 animal species. The free Veterinary Coronavirus Vaccines Landscape had opened on September 9, 2026, under the Coronavirus Vaccines R&D Roadmap Initiative, with more than 150 candidates at launch.

CIDRAP builds each entry from publicly available information. The tool covers vaccines for domesticated animals and distinguishes development stage from target species. Search results place clinical candidates and commercial vaccines in the same searchable record while keeping their status separate.

What does the tracker cover?

All 4 coronavirus genera appear in the database. CIDRAP sorts entries by development phase and target animal, which includes camelids—camels, alpacas and llamas—along with cattle, chickens, domestic cats, domestic dogs, mink and swine.

Three routes govern inclusion:

• Preclinical: testing in an animal model.
• Clinical: testing in the domesticated species meant to receive the vaccine.
• Commercial: commercial availability.

CIDRAP describes its scope as vaccines "either in development or commercially available."

Livestock and poultry dominate the catalog. A dvm360 review of the data exported November 11 counted 68 swine vaccines and 55 chicken vaccines. The November summary gives no count for cattle, camelids or mink.

What can companion-animal clinicians find?

The domestic dog section contains 8 entries: 7 commercially available products from Elanco, Merck Animal Health and Zoetis, plus 1 clinical-phase candidate. The domestic cat section contains 6 entries: 1 commercially available product, 4 clinical-phase candidates and 1 preclinical candidate.

The commercial feline entry is Zoetis’ Felocell FIP. The preclinical entry is a messenger RNA candidate from the University of California, Davis, listed as LNP-mRNA FIP. One of the 4 clinical-phase feline candidates is also listed for mink.

A typical record identifies the developer or manufacturer, intended species and development phase. The published summary provides no safety or efficacy outcomes for the individual canine and feline listings.

What does each record show?

A typical record names the target virus, developer or manufacturer and intended species, along with the vaccine platform, strain, antigen and adjuvant. It also flags documented passive immunity passed from dam to offspring, evidence of natural human infection with the target virus, and whether a corresponding human vaccine exists.

Route of administration and number of doses appear only for clinical-phase and commercial vaccines. Users can search by keyword and download the data as a CSV file. For a commercial vaccine’s approval, CIDRAP says the countries listed are "a sample, not a complete list."

What regulatory information does it provide?

Regulatory detail is limited. CIDRAP searches USDA Animal and Plant Health Inspection Service product summaries and a code book and the European Union’s Veterinary Medicinal Products Database, but the published description gives no individual FDA CVM, EMA or USDA approval decision for Felocell FIP or any other entry.

"Commercial availability" stands as an inclusion category, not a reported agency approval. The incomplete country list further limits any conclusion about where a commercial vaccine has authorization.

How were the candidates identified?

The CIDRAP team searches PubMed, USDA APHIS product summaries and a code book, the EU Veterinary Medicinal Products Database, published reviews of veterinary vaccines and veterinary industry websites. The Coalition for Epidemic Preparedness Innovations supports the database’s development and maintenance.

The University of Bergen and CIDRAP identified the candidates included at launch. CIDRAP says it updates the listings regularly and accepts questions and suggestions through a feedback form on the database page.

The veterinary database sits alongside the Coronavirus Vaccine Technology Landscape as one of the initiative’s 2 vaccine landscapes.

What changes at the exam table and in the barn?

• Companion animals: The canine and feline sections give clinicians a compact starting point: 8 dog entries, of which 7 are commercial, and 6 cat entries, of which 1 is commercial. A typical record supplies the manufacturer, species and phase, but the source provides no individual approval decisions or clinical outcomes.

• Food animals: Swine and chickens account for most of the catalog, with 68 and 55 entries, respectively; cattle and camelids also appear. For producers and food-animal clinicians, the phase filters separate development programs from commercially available vaccines, while the partial country list does not establish approval in every jurisdiction.

• Public health: The fields for documented dam-to-offspring passive immunity, natural human infection and the existence of a corresponding human vaccine place each animal program in an epidemiologic context. Those fields do not establish that a veterinary vaccine prevents human infection, and the source makes no such claim.

As CIDRAP updates the listings regularly and receives questions through its feedback form, the tracker’s value will depend on the completeness of each species, phase and approval record, not merely the headline count.